Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amprenavir

FDA-approved product (capsule, oral), marketed as Agenerase.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amprenavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amprenavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amprenavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

    NCT00296504 · start 2001-11

    Registered record
    Registry ID
    NCT00296504
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    fosamprenavir (GW433908); ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2010-10
    Enrolment
    753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Interventionfosamprenavir (GW433908); ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

    NCT00038519 · start 2001-04

    Registered record
    Registry ID
    NCT00038519
    Conditions
    HIV Infections
    Interventions
    Amprenavir/ritonavir; Saquinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAmprenavir/ritonavir; Saquinavir/ritonavir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

    NCT00038532 · start 2001-04

    Registered record
    Registry ID
    NCT00038532
    Conditions
    HIV Infections
    Interventions
    Amprenavir/ritonavir; Saquinavir/ritonavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-04
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAmprenavir/ritonavir; Saquinavir/ritonavir; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

    NCT00005762 · start 2001-03

    Registered record
    Registry ID
    NCT00005762
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Amprenavir; Nelfinavir mesylate; Efavirenz; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-03
    Completion
    2004-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Amprenavir; Nelfinavir mesylate +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.

    NCT00196625 · start 2000-11

    Registered record
    Registry ID
    NCT00196625
    Conditions
    HIV Infections
    Interventions
    Amprenavir (drug); ABT-378/r (drug); Ritonavir (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-11
    Completion
    2002-02
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAmprenavir (drug); ABT-378/r (drug); Ritonavir (drug)
    PhasePhase 2
    Registry statusCompleted

  • Once-Daily Drug Regimen for HIV-Infected Patients

    NCT00001968 · start 2000-01

    Registered record
    Registry ID
    NCT00001968
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    Amprenavir; Ritonavir; Abacavir; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-01
    Completion
    2000-11
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionAmprenavir; Ritonavir; Abacavir; Lamivudine
    PhasePhase 1
    Registry statusCompleted

  • Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

    NCT00001119 · start 1999-10

    Registered record
    Registry ID
    NCT00001119
    Conditions
    HIV Infections
    Interventions
    Tetanus Toxoid Vaccine; Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Abacavir sulfate; Amprenavir; Efavirenz; Hepatitis B Vaccine (Recombinant); Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1999-10
    Completion
    Not recorded
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTetanus Toxoid Vaccine; Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir +6 more
    PhaseNot applicable
    Registry statusCompleted

  • Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

    NCT00000940 · start 1999-05

    Registered record
    Registry ID
    NCT00000940
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Abacavir sulfate; Amprenavir; Lamivudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-05
    Completion
    2006-10
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Abacavir sulfate; Amprenavir; Lamivudine +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

    NCT00002239 · start 1999-05

    Registered record
    Registry ID
    NCT00002239
    Conditions
    HIV Infections
    Interventions
    Enfuvirtide; Ritonavir; Abacavir sulfate; Amprenavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-05
    Completion
    Not recorded
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEnfuvirtide; Ritonavir; Abacavir sulfate; Amprenavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

    NCT00002245 · start 1999-04

    Registered record
    Registry ID
    NCT00002245
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Amprenavir; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-04
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Amprenavir; Lamivudine
    PhasePhase 3
    Registry statusCompleted

  • Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

    NCT00001758 · start 1997-11

    Registered record
    Registry ID
    NCT00001758
    Conditions
    HIV Infection
    Interventions
    Abacavir; Amprenavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-11
    Completion
    2003-08
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionAbacavir; Amprenavir; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

    NCT00000912

    Registered record
    Registry ID
    NCT00000912
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Abacavir sulfate; Amprenavir; Nelfinavir mesylate; Efavirenz; Levocarnitine; Adefovir dipivoxil; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-05
    Enrolment
    475

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Abacavir sulfate; Amprenavir; Nelfinavir mesylate +4 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

    NCT00000918

    Registered record
    Registry ID
    NCT00000918
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir; Efavirenz; Saquinavir; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir +6 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

    NCT00000919

    Registered record
    Registry ID
    NCT00000919
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Hydroxyurea; Abacavir sulfate; Amprenavir; Nelfinavir mesylate; Efavirenz; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-11
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Hydroxyurea +8 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

    NCT00001085

    Registered record
    Registry ID
    NCT00001085
    Conditions
    HIV Infections
    Interventions
    Amprenavir; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-09
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAmprenavir; Lamivudine; Zidovudine
    PhasePhase 2
    Registry statusCompleted